Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing glycoprotein B of infectious laryngotracheitis virus and chicken IL-18

Chen, Hongying; Cui, Pei; Bao-an, Cui; Li, Heping; Jiao, Xian-Qin; Zheng, Lan-Lan; Cheng, Guo Feng; Chao, An-Jun

doi:10.1111/j.1574-695x.2011.00850.x

Cited by 25 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-18 is a strong IFN-␥-inducing factor that enhances immune responses when used as an adjuvant. The concept of using IL-18 to boost immune responses after vaccination has been investigated for chicken vaccines (23,24,32,(36)(37)(38). Hung et al (21) described that the full-length and mature chicken IL-18 purified recombinant protein effectively enhanced cell-mediated and humoral immunity.…”

Section: Discussionmentioning

confidence: 99%

A Eukaryotic Expression Plasmid Carrying Chicken Interleukin-18 Enhances the Response to Newcastle Disease Virus Vaccine

Wang¹,

Li²,

Zhang³

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Interleukin-18 (IL-18) is an important cytokine involved in innate and acquired immunity. In this study, we cloned the fulllength chicken IL-18 (ChIL-18) gene from specific-pathogen-free (SPF) chicken embryo spleen cells and provided evidence that the ChIL-18 gene in a recombinant plasmid was successfully expressed in chicken DT40 cells. ChIL-18 significantly enhanced gamma interferon (IFN-␥) mRNA expression in chicken splenocytes, which increased IFN-␥-induced nitric oxide (NO) synthesis by macrophages. The potential genetic adjuvant activity of the ChIL-18 plasmid was examined in chickens by coinjecting ChIL-18 plasmid and inactivated Newcastle disease virus (NDV) vaccine. ChIL-18 markedly elevated serum hemagglutination inhibition (HI) titers and anti-hemagglutinin-neuraminidase (anti-HN)-specific antibody levels, induced the secretion of both Th1-(IFN-␥) and Th2-(interleukin-4) type cytokines, promoted the proliferation of T and B lymphocytes, and increased the populations of CD3؉ T cells and their subsets, CD3 ؉ CD4 ؉ and CD3 ؉ CD8 ؉ T cells. Furthermore, a virus challenge revealed that ChIL-18 contributed to protection against Newcastle disease virus challenge. Taken together, our data indicate that the coadministration of ChIL-18 plasmid and NDV vaccine induces a strong immune response at both the humoral and cellular levels and that ChIL-18 is a novel immunoadjuvant suitable for NDV vaccination. N ewcastle disease (ND) is a serious avian disease that causes substantial economic loss and remains a major threat to the poultry industry (1, 2). Outbreaks of ND among poultry occur worldwide, and the pathogenic form of the virus is a disease listed in the World Organization for Animal Health (OIE) Terrestrial Animal Health Code and must be reported to the OIE (3), which results in severe trade limitations (4, 5). Currently, vaccination is the major tool for controlling infection by Newcastle disease virus (NDV). The NDV vaccine strains LaSota, B1, Mukteswar, and V4 are used widely in China. However, virulent NDV strains are still frequently isolated in vaccinated birds, indicating that NDV remains an ongoing threat to commercial flocks of birds (6). Therefore, it is necessary to develop more efficacious vaccines to prevent NDV infection.Many techniques have been developed to increase the immunogenicity of vaccines. Among these, cytokines are effective immunomodulators in animal models or in clinical testing (7-10). Among the large number of cytokines, interleukin-18 (IL-18) is a strong stimulator of T helper type 1 (Th1) responses and activates natural killer (NK) cells, stimulates the synthesis of other immunoactive cytokines from Th1 cells, monocytes, and NK cells, and synergizes with IL-12 in the maturation of Th1 cells and the suppression of IgE synthesis by B cells (11-13). Thus, IL-18 functions as an adjuvant (14, 15). However, depending on the cytokine environment, IL-18 may also promote Th2-type responses (16,17) and antibody formation (18).The isolation and characterization of chicken IL-18 (ChIL-18) ...

show abstract

Section: Discussionmentioning

confidence: 99%

A Eukaryotic Expression Plasmid Carrying Chicken Interleukin-18 Enhances the Response to Newcastle Disease Virus Vaccine

Wang¹,

Li²,

Zhang³

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…CD4 ϩ cells may directly produce antiviral cytokines, which increase B cell activity and promote the proliferation, maturation, and functional activity of CD8 ϩ CTLs, thus playing a critical role in controlling IBV infection (48,49). The ratio of CD4 ϩ /CD8 ϩ cells has been widely shown to be indicative of the general immune system status (50,51). In this study, the CD4 ϩ /CD8 ϩ ratio showed no significant (P Ͻ 0.05) variation among the groups until 14 doa.…”

Section: Fig 7 Means Of Histopathological Scores Of Lesions In Trachementioning

confidence: 99%

Mucosal, Cellular, and Humoral Immune Responses Induced by Different Live Infectious Bronchitis Virus Vaccination Regimes and Protection Conferred against Infectious Bronchitis Virus Q1 Strain

Chhabra

Forrester

Lemière

et al. 2015

Clin Vaccine Immunol

View full text Add to dashboard Cite

The objectives of the present study were to assess the mucosal, cellular, and humoral immune responses induced by two different infectious bronchitis virus (IBV) vaccination regimes and their efficacy against challenge by a variant IBV Q1. One-day-old broiler chicks were vaccinated with live H120 alone (group I) or in combination with CR88 (group II). The two groups were again vaccinated with CR88 at 14 days of age (doa). One group was kept as the control (group III). A significant increase in lachrymal IgA levels was observed at 4 doa and then peaked at 14 doa in the vaccinated groups. The IgA levels in group II were significantly higher than those in group I from 14 doa. Using immunohistochemistry to examine changes in the number of CD4 ؉ and CD8؉ cells in the trachea, it was found that overall patterns of CD8 ؉ cells were dominant compared to those of CD4 ؉ cells in the two vaccinated groups. CD8؉ cells were significantly higher in group II than those in group I at 21 and 28 doa. All groups were challenged oculonasally with a virulent Q1 strain at 28 doa, and their protection was assessed. The two vaccinated groups gave excellent ciliary protection against Q1, although group II's histopathology lesion scores and viral RNA loads in the trachea and kidney showed greater levels of protection than those in group I. These results suggest that greater protection is achieved from the combined vaccination of H120 and CR88 of 1-day-old chicks, followed by CR88 at 14 doa. T he prevention of infectious bronchitis (IB) in chickens isachieved through the use of live and inactivated vaccines, which provide protection against virulent field IB viruses (IBVs) in the event of an exposure. Despite these preventative measures, outbreaks of IB frequently occur in many poultry producing countries (1-3). This is probably due to the emergence of new variants of infectious bronchitis virus (1-5). For the successful protection of chickens against infection, it is essential to identify the prevalent genotypes in the region, determine the cross-protective potential of available vaccines, and optimize strategic vaccination programs.IB was first described in the United States during the 1930s and was identified in the United Kingdom in 1948. Thereafter, many IBV variants were isolated from Europe, significantly a variant called 793B that emerged in the 1990s (6). Later, IBV QX was first identified in China (7) before spreading to Europe (8). Another IBV genotype, Q1, genetically and serologically distinct from the classical IBVs, was also reported in China (9), the Middle East (10), and Europe (11). To contain this strain, an effective vaccination program is needed. However, very little is known about the cross protection induced by the commercially available vaccines or vaccination regimes against this variant Q1.An effective and long-lasting protection against IBV infection requires the activation of effector, memory cell-mediated, and humoral immune responses (HIRs) against the virus (12). A number of studies have reported the systemi...

show abstract

“…It has been shown that the ILTV gB protein assembles into homodimers that are rapidly cleaved to form two disulphide-linked species (20). Recombinant fowlpox virus-vector vaccines expressing the ILTV gB gene, and a DNA vaccine containing the gB gene, have also been developed and have been shown to provide protective immunity in chickens (3,7,26,30).…”

mentioning

confidence: 99%

Chicken interferon gamma fold expression level and tracheal lesion score differences between commercial broiler chickens vaccinated with live and vectored ILT vaccines

Miskinis

Liman²,

Bischoff³

et al. 2019

Medycyna Weterynaryjna

View full text Add to dashboard Cite

Infectious laryngotracheitis (ILT) is a respiratory tract disease affecting chickens around the world. The disease generates severe production losses due to increased mortality, decreased egg production, delayed body weight gain, and a predisposition to other respiratory pathogens causing enormous economic losses to the intensive poultry industry. Two licensed vaccines, comprising live or vectored ILT, are available to control the disease. The present trial was conducted to determine changes in chicken interferon gamma fold expression levels in chicken spleens and to evaluate tracheal lesion scores before and after vaccination with live and vectored infectious laryngotracheitis vaccines. Broilers were kept under commercial conditions until 35 days of age. Spleen and trachea samples were taken at 14, 28, and 35 days of age. Tracheas were stained with H&E, histopathology was performed, and the INF-γ fold expression level in spleen samples was analyzed. In the spleens of birds vaccinated with the live ILT vaccine, the increase in INF-γ expression levels was statistically significantly (p < 0.01) lower at 28 days of age, or 7 days post vaccination, (trial 1) and higher at 35 days of age, or 14 days post vaccination, (both trials). At 7 days post vaccination with the live ILT vaccine, the mean tracheal lesion score was significantly higher (p < 0.01) than it was in the control group (both trials). At 14 days post vaccination with the live ILT vaccine, the mean tracheal lesion score was significantly higher (p < 0.05) than it was in the control group 3 (trial 1). No significant differences were found between the control group 3 and group 2, which was vaccinated with the vectored HVT/LT vaccine (both trials). The results of the histology of trachea lesions indicate that vaccination with live ILT may have induced early local immunity. The INF-γ analysis results might indicate that the birds in group 2 (HVT/LT) did not develop local immunity until 35 days of age From the practical point of view, the vectored ILT vaccine is more beneficial because of its ease of administration in the hatchery, lower labor cost, and the absence of clinical signs post vaccination. Its potential drawback, however, is poor local immunity and the slow onset of optimal immunity in commercial broiler chickens

show abstract

Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing glycoprotein B of infectious laryngotracheitis virus and chicken IL-18

Cited by 25 publications

References 32 publications

A Eukaryotic Expression Plasmid Carrying Chicken Interleukin-18 Enhances the Response to Newcastle Disease Virus Vaccine

A Eukaryotic Expression Plasmid Carrying Chicken Interleukin-18 Enhances the Response to Newcastle Disease Virus Vaccine

Mucosal, Cellular, and Humoral Immune Responses Induced by Different Live Infectious Bronchitis Virus Vaccination Regimes and Protection Conferred against Infectious Bronchitis Virus Q1 Strain

Chicken interferon gamma fold expression level and tracheal lesion score differences between commercial broiler chickens vaccinated with live and vectored ILT vaccines

Contact Info

Product

Resources

About